Founded by experienced industry veterans, Angex focuses on genetically defined cancers and biomarker-driven patient populations with specific mutations and acquired resistance. They are developing a range of drug candidates in immuno-oncology, kinase inhibitors, and epigenetics, with the potential to revolutionize cancer therapies and precision medicines. Several programs are currently undergoing IND-enabling studies in preparation for clinical trials. Angex Pharmaceutical is an IND-approved innovative drug discovery company.